Shield Therapeutics PLC Feraccru licence agreement for Switzerland (2245K)
July 06 2017 - 1:00AM
UK Regulatory
TIDMSTX
RNS Number : 2245K
Shield Therapeutics PLC
06 July 2017
Shield Therapeutics plc and Ewopharma AG
("Shield" or the "Group", "Ewopharma")
Feraccru licence agreement for Switzerland
London, UK, 6 July 2017: Shield Therapeutics plc (LSE:STX), a
speciality pharmaceutical company focused on secondary care, and
Ewopharma AG, a pharmaceutical marketing company headquartered in
Schaffhausen, Switzerland, are pleased to announce that they have
entered into an exclusive sale, supply, distribution and marketing
agreement for Feraccru(R) in Switzerland.
Under the terms of the agreement, Shield will continue to manage
all regulatory aspects of Feraccru's initial marketing
authorisation and planned future label expansion, supply product as
well as provide significant product training and support for the
brand, whilst Ewopharma will be responsible for all aspects of
pricing, reimbursement, marketing and distribution.
Switzerland is a well-developed market for the treatment of Iron
Deficiency Anaemia (IDA), currently contributing almost 15% of
total European IV iron sales. With its existing expertise in the
IDA market and focus on gastroenterology, both parties believe
Ewopharma is ideally positioned to launch Feraccru into the Swiss
market and that Feraccru will represent a well matched, integral
addition to Ewopharma's existing portfolio.
Having recently extended Shield's distribution agreement with
AOP Pharmaceuticals to include the commercialisation of Feraccru in
Scandinavia (as previously announced), this agreement further
illustrates the execution of Shield's stated strategy to pursue
geographic expansion of Feraccru commercialisation outside its core
markets of the EU-5 and the USA. The detailed commercial terms of
the deal are not disclosed although Shield will receive an upfront
fee, is eligible to receive further milestone payments based on
regulatory and commercial achievements and will have an on-going
economic interest in the commercial success of Feraccru in the
territory.
Carl Sterritt, Chief Executive Officer and Founder of Shield
Therapeutics, commented: "The agreement entered into today further
validates our commitment to roll-out of Feraccru to patients in
multiple geographies as quickly as possible. It also reflects the
Group's strategy to maximise value for stakeholders through an
appropriate mix of self-commercialisation in core markets and
licensing in other geographies. We are very pleased to partner with
Ewopharma who are ideally placed to commercialise Feraccru in
Switzerland and look forward to a successful collaboration in this
highly-developed market for IDA."
Alain Staub, Chief Executive Officer and Main Shareholder of
Ewopharma AG, adds: "Feraccru ideally fits our development strategy
as we intend to strengthen our iron deficiency franchise.
Switzerland is traditionally an IV iron market. We are therefore
delighted to introduce this innovative oral iron therapy and offer
our Swiss patients an easier, more convenient alternative. We look
forward to a long-term partnership with Shield."
-Ends-
For further information please contact:
+44 (0) 207 186
Shield Therapeutics plc 8500
Joanne Estell, Chief Financial
Officer
Karl Keegan, Corporate Development
Director
+41 (0) 52 633
Ewopharma AG 09 99
Reto Schaberl, Head Business
Development
Dr. Shila Schneider, Business
Development Manager
Nominated Adviser and Joint +44 (0)20 3100
Broker 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
+ 44 (0)20 7418
Joint Broker 8900
Peel Hunt LLP
James Steel/Dr. Christopher
Golden
+44 (0)203 709
Financial PR Adviser 5700
Consilium Strategic Communications shieldtherapeutics@consilium-comms.com
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company
focused on the commercialisation and development of late-stage,
hospital-focused pharmaceuticals, which address areas of unmet
medical need. Our clear purpose is to help our patients become
people again, by enabling them to enjoy the things that make the
difference in their everyday lives. The Group has a marketed
product, Feraccru(R), for the treatment of IDA in adult patients
with IBD which has exclusive IP rights until the mid-2030's. In
addition, the Group is developing PT20, a late-stage pharmaceutical
for the treatment of systemic phosphate accumulation
(hyperphosphatemia). Shield Therapeutics, headquartered in London,
is listed on LSE's AIM under the ticker STX. For more information
please visit www.shieldtx.com.
About Ewopharma AG
Ewopharma AG, headquartered in Schaffhausen (Switzerland), is a
pharmaceutical marketing company focused on Central Eastern Europe
and Switzerland. With more than 50 years' presence in the region,
Ewopharma has extensive knowledge of these markets and enjoys a
privileged position in the area. The company covers all aspects of
market access and commercialisation of ethical pharmaceutical and
consumer health products. Further information is available at
www.ewopharma.com.
About Feraccru(R)
Feraccru is Shield's lead product and is a novel therapy for the
treatment of IDA that received an initial marketing authorisation
across Europe in February 2016 for the treatment of adult IBD
patients with IDA. Feraccru is the first oral iron therapy to be
specifically approved for the treatment of IDA in patients with IBD
and Shield's initial target market for Feraccru for in-house
commercialisation is the approximately 300,000 IBD patients in the
EU-5, who have been diagnosed with IDA in IBD.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRUVOORBRABRAR
(END) Dow Jones Newswires
July 06, 2017 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024